Overcoming CDK4/6 Inhibitor Resistance in HR-Positive/HER2-Negative Breast Cancer

(MedPage Today) — In the decade since palbociclib (Ibrance) received FDA approval, results from multiple clinical trials have provided a strong evidence base to make cyclin-dependent kinase (CDK)4/6 inhibitors, in combination with endocrine therapy…